Celyad: Japan Deal On NKR-T Cancer Therapy
Edison | Jul 13, 2016 04:46AM ET
The Japanese pharmaceutical company Ono Pharmaceutical Ltd (T:4528) is jumping a therapeutic generation by licensing Celyad's (NASDAQ:CYAD) allogeneic preclinical NKR-T cancer cell therapy for Japan, Korea and Taiwan. Allogeneic NKR-T has the same action as the Phase I/II NKR-T autologous product; allogeneic versions could be mass produced and provided “off the shelf”. ONO paid €11.25m cash with €270.75m possible in milestones plus royalties. NKR-T is being tested in two haematological cancers with trials in solid tumours planned for early 2017. On an interim basis, until more data on NKR-T and C-Cure are available, the indicative value moves from €32 to €41 per share.
ONO buys into allogeneic
The NKR-T technology uses a ubiquitous set of ligands expressed on many cancerous cell types. These ligands are recognised by the natural killer NKG2 receptor. By creating T-cells with the NKG2 receptor added, a variety of cancer types, including solid tumours, in theory, can be targeted. Preclinical models of cancer support this. Currently, this is being trialled in autologous cell therapy where the patient’s own cells are harvested, transformed and transfused. The allogeneic version uses the same general mechanism, but is still preclinical. CAR approaches by other companies need a new ligand type every time unless the cancer types are very similar. This CAR complexity and cost explains ONO’s interest in allogeneic NKR-T: a single, mass produced cancer therapy against multiple cancers.
To read the entire report Please click on the pdf File
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.